Literature DB >> 6547151

Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.

A A Portale, B E Booth, B P Halloran, R C Morris.   

Abstract

The hyperparathyroidism characteristic of patients with moderate renal insufficiency could be caused by decreases in the plasma concentration of ionized calcium (Ca++) evoked by: (a) recurring increases in the plasma concentration of inorganic phosphorus that may be detectable only in the post-prandial period; (b) a reversible, phosphorus-mediated suppression of renal 25-hydroxyvitamin D-1 alpha-hydroxylase that decreases the plasma concentration of 1,25-dihydroxyvitamin D (1,25-(OH)2D) enough to decrease both gut absorption and bone resorption of Ca++; (c) both of these. In a group of eight children with moderate renal insufficiency, mean glomerular filtration rate (GFR) 45 +/- 4 (SE) ml/min per 1.73 M2, ages 6-17 yr, we tested these hypotheses by determining the effect of short term (5 d) restriction and supplementation of dietary intake of phosphorus on the plasma concentration of 1,25-(OH)2D, the serum concentrations of immunoreactive parathyroid hormone (iPTH) and phosphorus, and the fractional renal excretion of phosphorus ( FEPi ). When dietary phosphorus was normal, 1.2 g/d, the serum concentrations of phosphorus throughout the day were not greater than those of normal control children, and the serum concentrations of carboxyl-terminal iPTH (C-iPTH) were greater, 59 +/- 9 vs. 17 +/- 3 mu leq/ml, and unchanging; the serum concentration of intact-iPTH was also greater, 198 +/- 14 vs. 119 +/- 8 pg/ml. The plasma concentration of 1,25-(OH)2D was lower than that of age-matched controls, 27 +/- 3 vs. 36 +/- 2 pg/ml (P less than 0.01). When dietary phosphorus was restricted to 0.35 g/d, the plasma concentration of 1,25-(OH)2D increased by 60% to a mean value not different from that of normal controls, while serum concentrations of C-iPTH and intact-iPTH decreased by 25%, the latter concentration to a mean value not different from that of controls. FEPi decreased from 31 to 9%. When dietary phosphorus was supplemented to 2.4 g/d, the plasma concentration of 1,25-(OH)2D decreased 32%, while those of C-iPTH and intact-iPTH increased by 131 and 45%, respectively; FEPi increased from 27 to 53%. Plasma concentrations of 25-hydroxyvitamin D remained normal and unchanged, and GFR did not change when dietary phosphorus was manipulated. The data demonstrate that in children with moderate renal insufficiency: (a) A normal dietary intake of phosphorus in attended by a decreased circulating concentration of 1,25-(OH)2D and an increased concentration of iPTH, but not by recurring increases in the serum concentration of phosphorus at any time of the day; (b) Dietary phosphorus is, however, a major determinant of the circulating concentrations of both 1,25-(OH)2D and iPTH, which vary inversely and directly, respectively, with dietary intake of phosphorus, and increase and decrease, respectively, to normal values when phosphorus is restricted for 5 d; (c) Restriction and supplementation of dietary phosphorus induces changes in the serum concentration of iPTH that correlate strongly but inversely with those induced in the plasma concentration of 1,25-(OH)2D (r = -0.88, P < 0.001); and (d) The physiologic responsiveness of the renal tubule to changes in dietary phosphorus is to a substantial extent intact. The data provide support for the second hypothesis stated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547151      PMCID: PMC437069          DOI: 10.1172/JCI111365

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  74 in total

1.  The assay of 1alpha,25-dihydroxyvitamin D3: physiologic and pathologic modulation of circulating hormone levels.

Authors:  M R Haussler; D J Baylink; M R Hughes; P F Brumbaugh; J E Wergedal; F H Shen; R L Nielsen; S J Counts; K M Bursac; T A McCain
Journal:  Clin Endocrinol (Oxf)       Date:  1976       Impact factor: 3.478

2.  Response of 1alpha,25-dihydroxyvitamin D3 to hypocalcemia in human subjects.

Authors:  J P Bilezikian; R E Canfield; T P Jacobs; J S Polay; A P D'Adamo; J A Eisman; H F DeLuca
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

3.  Impaired parathyroid hormone metabolism in patients with chronic renal failure.

Authors:  J Freitag; K J Martin; K A Hruska; C Anderson; M Conrades; J Ladenson; S Klahr; E Slatopolsky
Journal:  N Engl J Med       Date:  1978-01-05       Impact factor: 91.245

4.  Study of intestinal absorption of calcium in patients with renal failure.

Authors:  J W Coburn; M H Koppel; A S Brickman; S G Massry
Journal:  Kidney Int       Date:  1973-04       Impact factor: 10.612

Review 5.  Hyperparathyroidism and renal failure.

Authors:  C D Arnaud
Journal:  Kidney Int       Date:  1973-08       Impact factor: 10.612

6.  On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake.

Authors:  E Slatopolsky; S Caglar; L Gradowska; J Canterbury; E Reiss; N S Bricker
Journal:  Kidney Int       Date:  1972-09       Impact factor: 10.612

7.  How important is phosphate in the pathogenesis of renal osteodystrophy?

Authors:  E Slatopolsky; W E Rutherford; K Hruska; K Martin; S Klahr
Journal:  Arch Intern Med       Date:  1978-05-15

8.  Phosphate excretion in chronic renal failure: evidence for a mechanism other than circulating parathyroid hormone.

Authors:  S Fotino
Journal:  Clin Nephrol       Date:  1977-12       Impact factor: 0.975

9.  1,25 Dihydroxy-vitamin D3 in normal man and patients with renal failure.

Authors:  A S Brickman; J W Coburn; S G Massry; A W Norman
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

10.  Radioreceptor assay for 1 alpha,25-dihydroxyvitamin D3.

Authors:  P F Brumbaugh; D H Haussler; R Bressler; M R Haussler
Journal:  Science       Date:  1974-03-15       Impact factor: 47.728

View more
  49 in total

1.  Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.

Authors:  Sharon M Moe; Miriam P Zidehsarai; Mary A Chambers; Lisa A Jackman; J Scott Radcliffe; Laurie L Trevino; Susan E Donahue; John R Asplin
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-23       Impact factor: 8.237

Review 2.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

Review 3.  Management of secondary hyperparathyroidism: how and why?

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2017-01-02       Impact factor: 2.801

4.  Lack of FGF23 response to acute changes in serum calcium and PTH in humans.

Authors:  Katherine Wesseling-Perry; Hejing Wang; Robert Elashoff; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2014-07-25       Impact factor: 5.958

5.  The treatment of renal osteodystrophy.

Authors:  S P Rigden
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

6.  Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men.

Authors:  A A Portale; B P Halloran; R C Morris
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

7.  Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.

Authors:  S Lopez-Hilker; T Galceran; Y L Chan; N Rapp; K J Martin; E Slatopolsky
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

Review 8.  The kidney and bone metabolism: Nephrologists' point of view.

Authors:  Masafumi Fukagawa; Yasuhiro Hamada; Shohei Nakanishi; Motoko Tanaka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

9.  Parathyroid hormone gene expression in hypophosphatemic rats.

Authors:  R Kilav; J Silver; T Naveh-Many
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

10.  Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.

Authors:  E Slatopolsky; J Finch; M Denda; C Ritter; M Zhong; A Dusso; P N MacDonald; A J Brown
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.